Targeting vascular endothelial growth factor in angina therapy.
Despite tremendous success of growth factor therapy in animal models, clinical trials have demonstrated minimal success. Vascular endothelial growth factors are perhaps the most potent inducers of angiogenesis in these animal models. This review outlines the biology of vascular endothelial growth factors in the context of myocardial angiogenesis with an emphasis on its effects on the endothelium. It also provides an overview of delivery strategies and summarises the preclinical and clinical evidence relating to exogenous growth factor delivery for myocardial angiogenesis with an emphasis on the key future challenges.
Boodhwani
Munir
M
Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Ramlawi
Basel
B
Laham
Roger J
RJ
Sellke
Frank W
FW
D000787:Angina Pectoris / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D000818:Animals; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism* / Q000502:physiology
D002317:Cardiovascular Agents; D042461:Vascular Endothelial Growth Factor A